Skip to Content
  • Previous Rank
    -
  • Revenue 3 Yr Annual Growth Rate
    18%
  • Revenue 3 Yr Growth Rank
    83
  • EPS 3 Yr Annual Growth Rate
    28%
  • EPS 3 Yr Growth Rank
    71
  • Total Return 3 Yr Annual Rate
    66%
  • Total Return 3 Yr Rank
    6

Demand in China far exceeds supply for this biopharma company’s blood products, which it derives from human plasma.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

Location
Beijing, China
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-
Years on List1
CEO
David Xiaoying Gao
Websitehttp://www.chinabiologic.com
Incorporated in the United States.!Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$312
Net Income Past Four Quarters ($M)$92

Growth Rates and Ranks

Revenue 3 Yr Growth Rank83
EPS 3 Yr Annual Growth Rate28%
EPS 3 Yr Growth Rank71
Total Return 3 Yr Annual Rate66%
Total Return 3 Yr Rank
6